Skip to main content
SpringerLink
Log in

Non-Rheumatic Immune-Related Adverse Events

  • Chapter
  • First Online:
Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy

  • 361 Accesses

Abstract

With expanding use of immune-checkpoint inhibitors (ICIs), the incidence of immune-related adverse events (irAEs) is increasing, posing a new clinical challenge for practitioners. The spectrum and incidence of irAEs differ by the immune checkpoint molecule that is blocked, such that CTLA-4 inhibitors are associated with colitis and hypophysitis, while PD-1/PD-L1 inhibitors with pneumonitis and thyroiditis. However, despite ICI type, irAEs can affect every organ system in the body. Improved irAE outcomes are related to their timely recognition and management. This chapter explores what is known about the epidemiology, risk factors, diagnosis, management, and outcomes of non-rheumatic irAEs. In addition, we include an examination of late-breaking research into the prevention and management of irAEs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.

    Article  CAS  PubMed  Google Scholar 

  2. Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–42.

    Article  CAS  PubMed  Google Scholar 

  3. US Dept of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Version 5.0. US Dept of Health and Human Services. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf

  4. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S, Guo Y, Cai S, Wang Y, Li J. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+ IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019;7(1):341.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Carlino MS, Long GV. Ipilimumab combined with Nivolumab: a standard of Care for the Treatment of advanced melanoma? Clin Cancer Res. 2016;22(16):3992–8.

    Article  CAS  PubMed  Google Scholar 

  8. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol. 2017;86(4):614–20.

    Article  CAS  Google Scholar 

  10. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti–programmed Death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17.

    Article  CAS  PubMed  Google Scholar 

  11. Abdel-Rahman O, El Halawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol. 2016;12(3):413–25.

    Article  CAS  PubMed  Google Scholar 

  12. Connolly C, Bambhania K, Naidoo J. Immune-related adverse events: a case-based approach. Front Oncol. 2019;9(530):1–15

    Google Scholar 

  13. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(3):255–89.

    Article  CAS  Google Scholar 

  14. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv264–6.

    Article  CAS  PubMed  Google Scholar 

  15. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(17):1714–68.

    Article  CAS  Google Scholar 

  18. Aarli JA. The immune system and the nervous system. Sur Prog. 1983;229:137–54.

    CAS  Google Scholar 

  19. Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kamath SD, Kumthekar PU. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Frontiers in oncology. 2018;8(414):1–7.

    Google Scholar 

  21. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13(4):278–80.

    Article  PubMed  Google Scholar 

  22. Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8.

    Article  CAS  PubMed  Google Scholar 

  23. Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2017;27(2):152–4.

    Article  PubMed  Google Scholar 

  24. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29(6):806–12.

    Article  CAS  PubMed  Google Scholar 

  25. Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol. 2016;17(12):e529–41.

    Article  PubMed  Google Scholar 

  26. Cuzzubbo S, Tissier M. Neurological adverse events associated with the immune checkpoint inhibitors: review of the literature and characterization of the neurological patterns. Neuro-Oncology. 2016;18(suppl_4):iv25–6.

    Article  PubMed Central  Google Scholar 

  27. Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, et al. Neurologic complications of immune checkpoint inhibitors. J Neuro-Oncol. 2018;137(3):601–9.

    Article  CAS  Google Scholar 

  28. Dubey D, David W, Amato A, Reynolds K, Clement N, Chute D, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019;93(11):e1093–103.

    Article  CAS  PubMed  Google Scholar 

  29. Blackmon JT, Viator TM, Conry RM. Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromed. 2016;1(4):39–45.

    Article  Google Scholar 

  30. Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344(0):229–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Feng S, Coward J, McCaffrey E, Coucher J, Kalokerinos P, O'Bryne K. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol. 2017;12(11):1626–35.

    Article  PubMed  Google Scholar 

  32. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16(4):589–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. 2016;12(1):1–13.

    Article  PubMed  Google Scholar 

  34. Shah S, Dunn-Pirio A, Luedke M, Morgenlander J, Skeen M, Eckstein C. Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurolog Med. 2018:1–4.

    Google Scholar 

  35. Zafar Z, Vogler C, Hudali T, Bhattarai M. Nivolumab-associated acute demyelinating encephalitis: a case report and literature review. Clin Med Res. 2019;17(1–2):29–33.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Segreti J, Harris AA. Acute bacterial meningitis. Infect Dis Clin N Am. 1996;10(4):797–809.

    Article  CAS  Google Scholar 

  37. Logan SA, MacMahon E. Viral meningitis. BMJ. 2008;336(7634):36–40.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, Gadoth A, Smith CY, Bryant SC, Klein CJ, Aksamit AJ. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1):166–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Williams TJ, Benavides DR, Patrice K, Dalmau JO, Ávila d, Ribeiro AL, Le DT, et al. Association of Autoimmune Encephalitis with Combined Immune Checkpoint Inhibitor Treatment for metastatic Cancer. JAMA Neurol. 2016;73(8):928–33.

    Article  PubMed  Google Scholar 

  40. Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard M, Grob J. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36(1):77–8.

    Article  PubMed  Google Scholar 

  42. Sepúlveda M, Martinez-Hernandez E, Gaba L, Victoria I, Sola-Valls N, Falgàs N, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle Nerve. 2017;56(6):E162–7.

    Article  PubMed  CAS  Google Scholar 

  43. Mansoukis G, Koch J, Sommerville RB, EL-Dokla A, Harms MB, AL-Lozi MT, et al. Multifocal radiculopathy during Ipilimumab treatment of melanoma. Muscle Nerve. 2013;48:440–4.

    Article  CAS  Google Scholar 

  44. Supakornnumporn S, Katirji B. Guillain-Barre syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis. 2017;19(2):80–3.

    Google Scholar 

  45. Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S. How we treat neurological toxicity from immune checkpoint inhibitors. ESMO open. 2019;4(Suppl 4):1–5.

    Google Scholar 

  46. Thaipisuttikul I, Chapman P, Avila E. Peripheral neuropathy associated with Ipilimumab: a report of two cases. J Immunother. (Hagerstown, Md.: 1997). 2015;38(2):77.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol. 2019;130(8):1440–5.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Wijdicks EF, Klein CJ. Guillain-barre syndrome. In: Mayo Clinic Proceedings 1 Mar 2017, vol. 92, no. 3. Elsevier. p. 467–79.

    Google Scholar 

  49. Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’the immune system. Therapeutic advances in neurological disorders. 2018;11:1–9.

    Google Scholar 

  50. Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–34.

    Article  CAS  PubMed  Google Scholar 

  51. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–36.

    Article  CAS  PubMed  Google Scholar 

  52. Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018;6(1):83.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Fukasawa Y, Sasaki K, Natsume M, Nakashima M, Ota S, Watanabe K, Takahashi Y, Kondo F, Kozuma K, Seki N. Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol. 2017;10:809–12.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017;27(3):266–8.

    Article  PubMed  Google Scholar 

  55. Johnson DB, et al. Myasthenia gravis induced by Ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33(33):e122–4.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Chen JH, et al. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore). 2017;96(50):e9262.

    Article  Google Scholar 

  57. Becquart O, Lacotte J, Malissart P, Nadal J, Lesage C, Guillot B, et al. Myasthenia gravis induced by immune checkpoint inhibitors. J Immunother. 2019;42(8):309–12.

    Article  CAS  PubMed  Google Scholar 

  58. Bennett DLH, Mills KR, Riordan-Eva P, Barnes PRJ, Rose MR. Anti-MuSK antibodies in a case of ocular myasthenia gravis. J Neurol Neurosurg Psychiatry. 2006;77(4):564–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Montes V, Sousa S, Pita F, Guerreiro R, Carmona C. Myasthenia gravis induced by ipilimumab in a patient with metastatic melanoma. Frontiers in neurology. 2018;9(150)1–3.

    Google Scholar 

  60. Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmun Dis. 2011:1–5.

    Google Scholar 

  61. Trouth AJ, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmun Dis. 2012:1–10.

    Google Scholar 

  62. Maggi L, Mantegazza R. Treatment of myasthenia gravis. Clin Drug Investig. 2011;31(10):691–701.

    Article  CAS  PubMed  Google Scholar 

  63. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–78.

    Article  CAS  PubMed  Google Scholar 

  64. de Andrade FA, Fiorot SH, El B, Provenzano J, Martins VJ, Levy RA. The autoimmune diseases of the eyes. Autoimmun Rev. 2016;15(3):258–71.

    Article  PubMed  CAS  Google Scholar 

  65. Chang CJ, Chen SJ, Hwang DK, Liu CJ. Bilateral anterior uveitis after immunotherapy for malignant melanoma. Taiwan J Ophthalmol. 2018;8(3):173–5. https://doi.org/10.4103/tjo.tjo_88_17.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Fang T, Marberley DA, Ethminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31:319–22.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Conrady C, Conrady C, Larochelle M, Larochelle M, Pecen P, Pecen P, et al. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2018;256(1):187–91.

    Article  PubMed  Google Scholar 

  68. Aaberg MT, Aaberg TM. Pembrolizumab administration associated with posterior uveitis. Retinal Cases Brief Rep. 2016;11(4):1–351.

    Google Scholar 

  69. Kim JM, Materin MA, Sznol M, Kluger HM, Weiss S, Chow J, et al. Ophthalmic immune-related adverse events of immunotherapy: a single-site case series. Ophthalmology. 2019;126(7):1058–62.

    Article  PubMed  Google Scholar 

  70. Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of non-infectious uveitis. BTT. 2014;8:67–81.

    Google Scholar 

  71. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–53.

    Article  PubMed  Google Scholar 

  72. Cadranel J, Canellas A, Matton L, Darrason M, Parrot A, Naccache JM, Lavolé A, Ruppert AM, Fallet V. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. Eur Respir Rev. 2019;28(153):190058.

    Article  PubMed  Google Scholar 

  73. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced Cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–16.

    Article  PubMed  Google Scholar 

  74. Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, et al. Immune-related adverse events requiring hospitalization: Spectrum of toxicity, treatment, and outcomes. J Oncol Pract. 2019;15(9):e825–34.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol. 14(3):494–502.

    Google Scholar 

  76. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017;9:207–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Balaji A, Verde F, Suresh K, Naidoo J. Pneumonitis from anti–PD-1/PD-L1 therapy. Cancer Netw. 2017;31(10):739–46.

    Google Scholar 

  79. Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med. 2018;6(6):472–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of Ipilimumab treatment of melanoma. Chest. 2013;143(3):858–61.

    Article  PubMed  Google Scholar 

  81. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with Ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Investig. 2019;129(10):4305–15.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. J Immunother Cancer. 2016;4(1):13.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Naidoo J, Cappelli L, Lipson EJ, Forde PM, Sharfman WH, Zhang J, Mammen J, Moseley K, Suresh K, Mehta S, Sander I. A multidisciplinary toxicity team for cancer immunotherapy-related adverse events. J Natl Compr Cancer Netw. 2019;17(6):712–20.

    Article  Google Scholar 

  85. Trinh S, Le A, Gowani S, La-Beck NM. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a Minireview of current clinical guidelines. Asia Pac J Oncol Nurs. 2019;6(2):154–60.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67(11):2056–67.

    Article  CAS  PubMed  Google Scholar 

  88. Cabanillas G. Immune related adverse events and their treatment in melanoma patients receiving ipilimumab. JCO. 2017;35(15_suppl):e14598-e14598.

    Article  Google Scholar 

  89. Gupta A, De Felice KM, Loftus EV, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406–17.

    Article  CAS  PubMed  Google Scholar 

  90. Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol. 2018;9:9.

    Google Scholar 

  91. Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book. 2012:174–7.

    Google Scholar 

  92. Zeimer M, Koukoulioti E, Simon JC, Berg T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017;66(3):657–9.

    Article  Google Scholar 

  93. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.

    Article  CAS  PubMed  Google Scholar 

  94. Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016;14(7):662–81.

    PubMed  Google Scholar 

  95. Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7(1):31.

    Article  PubMed  PubMed Central  Google Scholar 

  96. George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology. 2019;19(4):587–94.

    Article  CAS  PubMed  Google Scholar 

  97. Su Q, Zhang X, Zhang C, Hou Y, Yao Y, Cao B. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis. J Immunol Res. 2018:e1027323.

    Google Scholar 

  98. Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol. 2019:JCO1901674.

    Google Scholar 

  99. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7(1):1–8.

    Article  CAS  Google Scholar 

  100. Papaconstantinou HT, Thomas JS. Bacterial colitis. Clin Colon Rectal Surg. 2007;20(1):18–27.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200(5):W468–74.

    Article  PubMed  Google Scholar 

  102. Cramer P, Bresalier R. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep. 2017;19(1):1–9.

    Article  Google Scholar 

  103. Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3(1):e000278.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ Book. 2018;(38):13–19.

    Google Scholar 

  105. Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66(5):581–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Cheung V, Gupta T, Payne M, Middleton MR, Collier JD, Simmons A, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary Centre. Frontline Gastroenterol. 2019;10(4):364–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.

    Article  CAS  PubMed  Google Scholar 

  108. Gauci M, Baroudjian B, Zeboulon C, Pages C, Poté N, Roux O, et al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed? J Hepatol. 2018;69(2):548–50.

    Article  PubMed  Google Scholar 

  109. Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38(6):976–87.

    Article  PubMed  Google Scholar 

  110. Tsung I, Dolan R, Lao CD, Fecher L, Riggenbach K, Yeboah-Korang A, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther. 2019;50(7):800–8.

    Article  CAS  PubMed  Google Scholar 

  111. Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in Cancer therapy. Curr Radiol Rep. 2017;5(11):1–10.

    Google Scholar 

  112. Hsu C, Marshall JL, He AR. Workup and Management of Immune‐Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment. The oncologist. 2020;25(2):105–111.

    Google Scholar 

  113. Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31(6):965–73.

    Article  PubMed  Google Scholar 

  114. Zhang HC, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. J Immunother Cancer. 2019;7(1):47.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29(9):237.

    Article  Google Scholar 

  116. Sanjeevaiah A, Kerr T, Beg MS. Approach and management of checkpoint inhibitor-related immune hepatitis. J Gastrointest Oncol. 2018;9(1):220–4.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Delanoy N, Michot J, Comont T, Kramkimel N, Lazarovici J, Dupont R, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6(1):e48–57.

    Article  PubMed  Google Scholar 

  118. Kohlmann J, Wagenknecht D, Simon J, Ziemer M. Immune-related pancreatitis associated with checkpoint blockade in melanoma. Melanoma Res. 2019;29(5):549–52.

    Article  PubMed  Google Scholar 

  119. Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with Nivolumab + Ipilimumab. J Natl Cancer Inst. 2017;109(4):1–3.

    Google Scholar 

  120. Saito H, Ono K. Nivolumab-induced pancreatitis: an immune-related adverse event. Radiology. 2019;293(3):521.

    Article  PubMed  Google Scholar 

  121. Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5(1):8.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Calvo R. Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia. Front Pharmacol. 2019;10:454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol. 2019;102:157–62.

    Article  PubMed  Google Scholar 

  124. Michot JM, Lazarovici J, Tier A, Champiat S, Voisin AL, Ebbo M, et al. Haematological immune-related adverse events with immune checkpoint inhibitos, how to manage? Eur J Cancer. 2019;122:72–90.

    Article  CAS  PubMed  Google Scholar 

  125. Papazafiropoulou A, Papanas N, Pappas S, Maltezos E, Mikhailidis DP. Effects of oral hypoglycemic agents on platelet function. J Diabetes Complicat. 2015;29(6):846–51.

    Article  Google Scholar 

  126. Karakas Y, Yuce D, Kılıckap S. Immune thrombocytopenia induced by Nivolumab in a metastatic non-small cell lung Cancer patient. Oncol Res Treat. 2017;40(10):621–2.

    Article  CAS  PubMed  Google Scholar 

  127. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.

    Article  CAS  PubMed  Google Scholar 

  128. Varricchi G, Galdiero M, Marone G, Criscuolo G, Triassi M, Bonaduce D, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2:e000247. https://doi.org/10.1136/esmoopen-2017-000247.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Salem J, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–89. https://doi.org/10.1016/S1470-2045(18)30608-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55. https://doi.org/10.1056/NEJMoa1609214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Yang S, Asnani A. Cardiotoxicities associated with immune checkpoint inhibitors. Curr Probl Cancer. 2018;42:422–32.

    Article  PubMed  Google Scholar 

  132. Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohé C. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer. 2016;99:117–9.

    Article  CAS  PubMed  Google Scholar 

  133. Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome.

    Google Scholar 

  134. de Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC. Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy. J Immunother. 2018;41:329–31.

    Article  PubMed  Google Scholar 

  135. Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5(1):6–14.

    PubMed  PubMed Central  Google Scholar 

  136. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.

    Article  CAS  PubMed  Google Scholar 

  138. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  139. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.

    Article  CAS  PubMed  Google Scholar 

  140. Larkin J, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  141. Robert C, Schachter J, Long G, Arance A, Grob J, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32. https://doi.org/10.1056/NEJMoa1503093.

    Article  CAS  PubMed  Google Scholar 

  142. Ito J, Fujimoto D, Nakamura A, Nagano T, Uehara K, Imai Y, Tomii K. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer. 2017;109:58–61.

    Article  PubMed  Google Scholar 

  143. Cortazar FB, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160–9.

    Article  CAS  PubMed  Google Scholar 

  145. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211–2.

    Article  CAS  PubMed  Google Scholar 

  146. Thajudeen B, et al. Ipilimumab granulomatous interstitial nephritis. Am J Ther. 2015;22(3):e84–7.

    Article  PubMed  Google Scholar 

  147. Shirali A, Perazella M, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016;68:287–91. https://doi.org/10.1053/j.ajkd.2016.02.057.

    Article  CAS  PubMed  Google Scholar 

  148. El Majzoub I, Qdaisat A, Thein K, Win M, Han M, Jacobson K, et al. Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med. 2019;73:79–87. https://doi.org/10.1016/j.annemergmed.2018.04.019.

    Article  PubMed  Google Scholar 

  149. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–82.

    Article  PubMed  Google Scholar 

  150. Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S. Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management. Case Rep Oncol. 2017;10(3):897–909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Usui Y, Udagawa H, Matsomoto S, Imai K, Ohashi K, Ishibashi M, et al. Association of serum anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by Nivolumab in patients with non-small cell lung cancer. J Thorac Oncol. 2017;12:e41–3.

    Article  PubMed  Google Scholar 

  152. Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death−1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76:863–70. https://doi.org/10.1016/j.jaad.2016.10.044.

    Article  PubMed  Google Scholar 

  153. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:1–11.

    Article  Google Scholar 

  154. Johnson D, Sullivan R, Menzies A. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904–11. https://doi.org/10.1002/cncr.30642.

    Article  PubMed  Google Scholar 

  155. Cappelli L, Dorak M, Bettinotti M, Bingham C, Shah A. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor induced inflammatory arthritis. Rheumatology. 2018;58:476–80. https://doi.org/10.1093/rheumatology/key358.

    Article  CAS  PubMed Central  Google Scholar 

  156. Suresh K, Voong K, Shankar B, Forde P, Ettinger D, Marrone K, et al. Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13:1930–9. https://doi.org/10.1016/j.jtho.2018.08.2035.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Aanika Balaji & Bairavi Shankar

  2. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, Baltimore, MD, USA

    Jarushka Naidoo

  3. Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University, Baltimore, MD, USA

    Jarushka Naidoo

Authors
  1. Aanika Balaji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bairavi Shankar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jarushka Naidoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jarushka Naidoo .

Editor information

Editors and Affiliations

  1. Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Maria E. Suarez-Almazor

  2. Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA

    Leonard H. Calabrese

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Balaji, A., Shankar, B., Naidoo, J. (2021). Non-Rheumatic Immune-Related Adverse Events. In: Suarez-Almazor, M.E., Calabrese, L.H. (eds) Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-56824-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56824-5_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56823-8

  • Online ISBN: 978-3-030-56824-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation